This course is available as part of the 2017 ASCO Tumor Boards bundle.
This is a case-based activity that includes discussion of a 65-year-old male, with no chronic medical problems but had a 40-pack year history of cigarette smoking. He presented with painless jaundice. In the past three months he has lost 20 pounds. His father, who was also a smoker, died from pancreatic cancer at the age of 73.
At the end of this course, learners should be able to:
- Describe the criteria for resectability for pancreatic adenocarcinoma
- Describe the evolution of adjuvant therapy clinical trials over the last three decades
- Acknowledge the different practice patterns regarding the utilization of adjuvant radiation therapy
- Review the data supporting the use of capecitabine and gemcitabine in the adjuvant treatment of ductal adenocarcinoma of the pancreas from the ESPAC-4 trial
- Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care
IMPORTANT NOTE: This course expires on January 18, 2020. Participants must complete all necessary course components by this date.